AbCellera Biologics's Total Assets for the quarter that ended in Jun. 2024 was €1,312.20 Mil.
Warning Sign:
If a company builds assets at 152.8% a year, faster than its revenue growth rate of 62.3% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, AbCellera Biologics's average Total Assets Growth Rate was 0.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 20.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 152.80% per year.
During the past 6 years, AbCellera Biologics's highest 3-Year average Total Assets Growth Rate was 277.80%. The lowest was 20.90%. And the median was 245.00%.
The historical data trend for AbCellera Biologics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
AbCellera Biologics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (STU:8QQ) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jun. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
AbCellera Biologics's Asset Turnover for the quarter that ended in Jun. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
AbCellera Biologics Total Assets Related Terms
Thank you for viewing the detailed overview of AbCellera Biologics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:8QQ has been successfully added to your 